Introduction

Mark Schneiderman is the founder, chief investment officer and managing member of Aquilo Capital Management. He has spent 25 years trying to explain that value in biotech would be synonymous was an oxymoron to most people. "We are intrigued because Evan and I kind of, you know, don't worship the shrine of Benjamin Graham and David Dodd, but we do... We are in value," he says.